Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors

NCT05572684 is registered in ClinicalTrials.gov with NextCure, Inc. as lead sponsor.

NCT NCT05572684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05572684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors
Lead sponsor
NextCure, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
October 6, 2022
Completion date
April 30, 2025
Enrollment
97 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, cervical cancer, colo-rectal cancer, endometrial cancer, esophageal cancer, gastric cancer, head neck cancer, lung cancer, microsatellite instability high, microsatellite instability low, microsatellite stable, ovarian cancer